Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given an average rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $23.00.

A number of equities analysts have recently commented on the company. Scotiabank raised their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. BTIG Research increased their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th.

Aura Biosciences Stock Down 1.8 %

Shares of NASDAQ:AURA opened at $7.85 on Friday. The firm has a market capitalization of $392.11 million, a PE ratio of -4.54 and a beta of 0.30. The company has a 50-day moving average price of $8.33 and a two-hundred day moving average price of $8.92. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. Analysts anticipate that Aura Biosciences will post -1.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now owns 151,693 shares in the company, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,778 shares of company stock worth $240,706. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently modified their holdings of AURA. Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after buying an additional 43,897 shares during the last quarter. State Street Corp boosted its holdings in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after acquiring an additional 26,841 shares during the period. Geode Capital Management LLC grew its position in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after acquiring an additional 39,379 shares during the last quarter. Wellington Management Group LLP purchased a new position in Aura Biosciences in the 3rd quarter worth approximately $1,037,000. Finally, Franklin Resources Inc. lifted its position in Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.